Vevo Therapeutics

Vevo Therapeutics

AI-driven in vivo drug discovery platform

About Vevo Therapeutics

Simplify's Rating
Why Vevo Therapeutics is rated
A-
Rated B on Competitive Edge
Rated A on Growth Potential
Rated A on Rating Differentiation

Industries

AI & Machine Learning

Biotechnology

Company Size

11-50

Company Stage

Seed

Total Funding

$11.7M

Headquarters

San Francisco, California

Founded

2022

Overview

Vevo Therapeutics specializes in drug discovery by using advanced AI models and its Mosaic platform to generate high-resolution in vivo data, which studies drug interactions within living organisms. This method allows them to identify new drug targets and candidates that traditional approaches might miss. They serve pharmaceutical companies and research institutions by providing insights into drug efficacy and gene expression at a single-cell level, making the drug discovery process faster and more cost-effective. The company's goal is to enhance drug development, leading to better treatments for a broader range of patients.

Simplify Jobs

Simplify's Take

What believers are saying

  • Rising demand for single-cell RNA sequencing boosts Mosaic platform's relevance.
  • AI-driven drug discovery is gaining traction in pharmaceutical industry.
  • Partnerships with academic institutions provide access to cutting-edge research.

What critics are saying

  • Intense competition from other AI-driven drug discovery platforms.
  • Rapid technological advancements may render current platform obsolete.
  • Data privacy concerns could lead to regulatory scrutiny.

What makes Vevo Therapeutics unique

  • Vevo uses Mosaic platform for high-resolution in vivo drug discovery.
  • AI models enhance Vevo's drug discovery by analyzing diverse patient data.
  • Single-cell RNA profiling offers insights into drug efficacy across patient populations.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$11.7M

Above

Industry Average

Funded Over

1 Rounds

Notable Investors:
Seed funding is usually the first official round after pre-seed, when a startup has a prototype or concept. It’s typically used to develop the product, test the market, and start building the team. Investors here are often angel investors or early-stage venture capitalists.
Seed Funding Comparison
Above Average

Industry standards

$3.3M
$2M
Netflix
$2.3M
Instacart
$3M
Robinhood
$12M
Vevo Therapeutics

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-3%

2 year growth

4%
BioSpace
Dec 5th, 2024
Vevo Therapeutics Partners with the Parse Biosciences GigaLab to Generate 100M Cell Atlas for AI Powered Drug Discovery

Vevo Therapeutics partners with the Parse Biosciences GigaLab to generate 100M cell atlas for AI powered drug discovery.

Hit Consultant
Dec 8th, 2022
Vevo Launches with $12M to Scale Vivo Data Generation to Discover Better Drugs

Vevo Therapeutics, an SF-based biotechnology company, launched today with a $12M seed round led by General Catalyst and Wing Venture Capital using its Mosaic in vivo drug discovery platform and next-generation AI models to uncover better drugs for more patients.

BioSpace
Dec 8th, 2022
Vevo Therapeutics Launches with Oversubscribed $12M Seed Financing to Discover Better Drugs Using Higher Resolution In Vivo Data Generated at Scale

Vevo Therapeutics, a biotechnology company using its Mosaic in vivo drug discovery platform and next generation AI models to uncover better drugs for more patients, launched today with an oversubscribed and upsized $12M seed financing round.

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for Vevo Therapeutics right now.

Find jobs on Simplify and start your career today

💡
We update Vevo Therapeutics's jobs every 8 hours, so check again soon! Browse all jobs →